corporation or public charity that specializes in assisting
cancer patients and increasing enrollment, retention and
minority participation in cancer clinical trials.
Amend Bill, page 5, line 8, by striking out the comma after
"trial" and inserting a semicolon
Amend Bill, page 5, lines 12 and 13, by striking out all of
said lines and inserting
(c) Expenses and registration.--The following apply:
(1) Government, industry, public and private
foundations,
Amend Bill, page 5, lines 17 through 20, by striking out
"third party nonprofit corporations and public charities that"
in line 17 and all of lines 18 through 20 and inserting
a third-party reimbursement entity.
(2) A third-party reimbursement entity shall register
with a department-approved Pennsylvania college or university
with a school of public health. Registration must occur
within 30 days of the date the third-party reimbursement
entity first reimbursed a patient-subject, or the patient-
subject's family, friends or chaperones, for travel or
ancillary expenses related to a cancer clinical trial
conducted within this Commonwealth.
(3) Registration under paragraph (2) shall include:
(i) The name of the third-party reimbursement
entity.
(ii) The third-party reimbursement entity's legal
and tax status.
(iii) The third-party reimbursement entity's
employer or other similar identification number.
(iv) The names of the third-party reimbursement
entity's principal officers and directors.
(v) The names of donors of $5,000 or more to the
third-party reimbursement entity.
(vi) Appropriate identifying information, as
determined by the department, regarding other sources of
funding from a source of $5,000 or more.
(vii) Other information as the department deems
necessary or appropriate.
(4) A third-party reimbursement entity registering under
paragraph (2) shall update the registration no less than once
annually utilizing forms and regulations developed by the
department.
(5) A third-party reimbursement entity that fails to
register as required by this subsection shall be subject to a
2018/90BIL/SB0576A06056 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44